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Monolith-based 68Ga processing: a new strategy
for purification to facilitate direct radiolabelling
methods†
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Nicole Pammea and Stephen J. Archibald*ab
The post-processing of 68Ga generator eluate by means of a novel
high capacity cation-exchange silica monolith column has been
validated in this work. Quantitative release of a purified 68Ga solu-
tion in high concentration can be achieved using weak acidic solu-
tions which can be directly used for chelator or conjugate labelling
in an injectable form with improved radiochemical characteristics.
The system has the potential to be incorporated in a flow based
microfluidic system for dose-on-demand radiotracer synthesis.
68Ga radiopharmaceuticals are of growing importance in
clinical positron emission tomography (PET) with the success
of octreotide derivatives for imaging neuroendocrine
tumours,1,2 and prostate specific membrane antigen (PSMA)
derivatives receiving significant recent interest.3,4 68Ga
generators have simultaneously been developed towards
routine clinical use5,6 with the Eckert and Ziegler generator
receiving recommendation from the EMA for pharmaceutical
approval and FDA documents filed in 2014. This generator is
based on a TiO2 solid phase in which the produced ionic
68Ga3+ is eluted as GaCl3 from the generator using a solution
of 0.1 N HCl.7 However, current 68Ge/68Ga radionuclide
generators do not have optimal properties for the direct
synthesis of 68Ga-labeled radiopharmaceuticals. The generator
eluate has a large volume (5–10 mL) with a high
concentration of H+ (pH < 1) and can contain metal ion
impurities (commonly aluminiumĲIII), ironĲIII) and zincĲII)).6,8
All of which can potentially hinder complexation formation
and reduce specific activity (SA). Thus, the eluate from a 68Ge/
68Ga generator cannot currently be directly used for preparing
radiopharmaceuticals that are in routine clinical practice.
This can be overcome by either; (a) advanced chelator de-
sign to allow for direct labelling of eluate, a trait which is so
far only proven successful with the highly promising
trisĲhydroxypyridinone) ligands developed by Blower, Ma and
co-workers9,10 or; (b) post-processing of the generator eluate
to allow for complexation, the approach nearly exclusively
followed by groups worldwide and the only method possible
for current clinically used tracers.
Several methods for the processing of the generator eluate
have been attempted in order to overcome the issues men-
tioned above including ion-exchange chromatography and
fractionation.7,8,11–13 All of which individually mitigate some
of the limitations of 68Ga complexation. However, to date, no
method delivers on all requirements to release the 68Ga puri-
fied from other metal ions into small volumes of low H+ con-
centration using a directly injectable solvent. Rösch and co-
workers use a particle-packed cation-exchange resin column
and ethanol (instead of the commonly used acetone) in the
elution mixture for post-processing of 68Ga eluate.14 Ethanol-
based post-processing provides a more acceptable reaction
mixture for the preparation and formulation of directly in-
jectable 68Ga-radiopharmaceuticals. However, the require-
ment for a higher concentration HCl solution (0.9 N) can
suppress the reactivity of chelators and also needs higher
concentrations of buffer to balance the pH.
Recently, miniaturised microfluidic-based systems have
attracted much attention in PET tracer synthesis.15,16 Such
microfluidic systems are easily shielded and therefore reduce
external impact and have significant potential to facilitate
PET tracer synthesis, reduce consumption of expensive re-
agents and improve reactivity. Most importantly, microfluidic-
based systems are compatible with automated dose-on-
demand requirements. However, it is difficult to incorporate
the current post-processing into microfluidic systems because
particle-packed resin columns are challenging to integrate
with microfluidic systems due to the relative high
backpressures generated. This is an obstacle in the design of
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an integrated microfluidic system for the dose-on-demand
tracer synthesis.
Owing to their small-size skeletons and mesoporous struc-
tures, monolith columns provide elevated permeability and
favourable mass transfer compared to particle-packed
columns.17–20 Due to these characteristics monolith columns
have shown their applications in a variety of chromato-
graphic modes.21–24 Importantly, the integration of monolith
columns with microfluidic systems has already been demon-
strated in an enzymatic reaction module.25 If a cation-
exchange monolith can purify 68Ga generator eluate, it would
therefore be possible to build an integrated system compris-
ing a monolith for ion-exchange and a microfluidic system
for performing flow-based 68Ga preparation and
radiolabelling in an automated dose-on-demand system. To
our knowledge there has been no reported use of a cation-
exchange monolith for the separation of 68Ga directly from
the 68Ge/68Ga generator eluate.
The aim of this work is to fabricate a cation-exchange sil-
ica monolith and evaluate its capability for efficient separa-
tion of 68Ga directly from the generator eluate. The prepara-
tion of injectable 68Ga-labeling pharmaceuticals can then be
investigated to determine whether the characteristics are im-
proved when compared to the best current method.
The silica monolith columns used in this work are porous
rods consisting of silica skeletons and interconnecting meso-
pores that give much higher permeability and favourable
mass transfer compared to particle-packed columns.26,27 They
were produced by the sol–gel method described in our previ-
ous study26 followed by surface modification with thiol
groups and oxidation to transform –SH to –SO3H (see ESI†).
Therefore forming a sulfonic acid functionalised monolith
capable of selectively trapping cations. BET nitrogen adsorp-
tion/desorption isotherm (see ESI† S5 and Fig. S3) shows typi-
cal hysteresis between adsorption and desorption, which is
consistent with the disordered mesoporous structure
displayed in the SEM (see Fig. 1) giving a specific surface area
of 238 m2 g−1 and pore volume of 0.75 cm3 g−1, with an aver-
age pore diameter of ∼13 nm. The cation exchange capacity
(CEC) quantifies the ability of a material to adsorb cations.
Analysis of our –SO3H monoliths gives a value of 180 μeq.
g−1, which is 30 times higher than a commercial solid phase
extraction (SPE) cation-exchange resin (for further CEC dis-
cussion see ESI† S4).
Due to shrinkage during the sol–gel processing it is chal-
lenging to make a monolith column within a conventional
stainless steel column without a void volume. Therefore,
commercially available monolith columns are usually con-
fined in heat-shrinkable polymer tubing.17,28 To avoid dam-
age to the functionalised monolith from the heating required
to mount the column tightly inside heating-shrinkable tub-
ing, the SiO2 monolith–SO3H rod was fixed in an empty Sep-
Pak Vac tube and a void volume between the monolith rod
and tube wall was packed with powdered functionalised
monolith (ca. 10% wt of total monolith mass) and plastic
frits fitted at both ends to form the SiO2 monolith–SO3H col-
umn (see Fig. 1).
As mentioned previously, the direct synthesis of 68Ga
tracers from the generator eluate is problematic. The most
common approach to overcome this is the transfer of the ini-
tial 68Ga eluate to a cation-exchange resin column. As it has a
high cation-exchange distribution coefficient, 68Ga can be
quantitatively adsorbed on the resin from the acidic generator
eluate and then eluted with HCl/acetone solutions.7,29,30 Al-
though the use of HCl/acetone solutions can efficiently purify
and concentrate the 68Ga eluate, SPE is required for the re-
moval of acetone and the recovery of the 68Ga-labeled com-
pounds. The use of ethanol in place of acetone provides the
potential for preparation of injectable 68Ga-radiopharmaceuti-
cals. However, the reactivity of the 68Ga solution released via
current methodologies is inadequate for high SA tracer forma-
tion due to metal ion impurities and currently used technolo-
gies are not compatible with microfluidic reactors, preventing
the design of automated compact dose-on-demand systems.
The SiO2 monolith–SO3H columns used in this work not
only quantitatively (98 ± 1%) adsorbed 68Ga3+ but also
exhibited highly efficient release of the 68Ga3+ in comparison
to commercial polymeric cation-exchange resins. For the elu-
tion methods (see Table 1), a multi-fraction elution process
showed a small advantage compared to single step method.
Larger amounts of ethanol and hydrochloric acid in the
washing solution (i.e. 85% EtOH/0.2 N HCl) result in a mod-
est amount (8%) of 68Ga being lost in the washing step.
When using 80% EtOH/0.1 N HCl and 90% EtOH/0.5 N HCl
Fig. 1 Schematic representation of the monolith based system for 68Ga processing and radiolabelling (left), photograph of cation-exchange silica-
monolith column (centre) and SEM image of SiO2 monolith–SO3H (right, scale bar: 20 μm).
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as washing and elution solutions respectively, the SiO2 mono-
lith–SO3H does not only efficiently purify
68Ga from other
metal ions (see Table 2) but also almost quantitatively (93%)
recovers 68Ga from the eluate. This compares to only 25% re-
covery for the AG50W column using the same conditions.14
It is postulated that the lower release efficiencies for the
resin indicate the strong affinity for 68Ga3+ within the cation-
exchange resin pores.31 These results suggest that the micro-
environment of the monolith columns used in this work fa-
vours ion-exchange processing for adsorption and desorption
of 68Ga3+.
A main benefit of our method is that the 68Ga can be con-
centrated up to ten-fold and the 68Ga elution requires a lower
concentration of hydrochloric acid (0.5 N) when compared
with the best published example.14 Decreasing the concentra-
tion of H+ allows lower concentration buffers to be used in
radiolabelling reactions. Metallic radiolabelling characteris-
tics are generally directly proportional to the concentration of
the two reagents in solution.9 Increase of 68Ga concentration
in this manner could have significant impact on future tracer
production by decreasing the amount of precursor required
for synthesis, therefore dramatically increasing the SA. In or-
der to ensure the purified 68Ga could still be used in stan-
dard labelling protocols and behaved analogously to reported
chelator reactions, two common galliumĲIII) chelators (DOTA
and NOTA) were selected for comparison of radiolabelling
characteristics (see Table 3 and Scheme 1). The monolith-
based system for 68Ga processing and labelling is shown in
Fig. 1. A yield of 97% was achieved for DOTA (95 °C, 10 min,
5 μM) which offers a two-fold decrease in the concentration
required for near quantitative conversion. The results are
more pronounced for NOTA, with 95% incorporation at 1 μM
(room temperature, 5 min). This is a ten-fold improvement
over the reported concentrations of 10 μM giving 80% RCY.9
Finally, a demonstration of clinical applicability was provided
by 68Ga radiolabelling of the licensed somatostatin targeted
agent DOTATOC,1 which produced near quantitative yields
within 10 minutes using standard kit precursor amounts.14
Complete synthesis of 68Ga-DOTATOC can be carried out,
from elution of the generator to delivery of the tracer, in 25
minutes. If all the generator eluate is used (740 MBq), the
tracer can be produced with a final SA of 41 GBq μmol−1,
Table 1 Ethanol-based post-processing of 68Ga on SiO2 monolith–SO3H (average of n = 3)
Entry Activity%a Washing solutionb Activity%c Elution solution Volume Activity%d
1 98 85% EtOH/0.2 N HCl 8.0 93% EtOH/0.9 N HCl 1 mL 90
2 99 80% EtOH/0.1 N HCl 0.3 96% EtOH/0.5 N HCl 1 mL 98
3 99 80% EtOH/0.1 N HCl 0.3 90% EtOH/0.9 N HCl 0.4 mL 94e
4 99 80% EtOH/0.1 N HCl 0.3 90% EtOH/0.5 N HCl 0.4 mL 93e
5 99 80% EtOH/0.1 N HCl 0.3 90% EtOH/0.5 N HCl 4 × 0.2 mL 98
6 99 80% EtOH/0.1 N HCl 0.6 90% EtOH/0.5 N HCl 0.5 mL 98
7 99 80% EtOH/0.1 N HCl 0.6 90% EtOH/0.2 N HCl 1 mL 94
8 f 98 80% EtOH/0.2 N HCl 0.1 90% EtOH/0.9 N HCl 1 mL 46
9 f 98 80% EtOH/0.1 N HCl 0.1 90% EtOH/0.2 N HCl 1 mL 16
a Activity trapped in monolith. b Volume of washing solution was 1 mL. c Activity in washing solution. d Activity in elution solution. e Release
activity increases to ≥98% with 1 mL. f Commercial cation-exchange resin (SCX). Solvent compositions are given in v/v.











Before 1140 74 320 420 25
After 35 52 6 1 Undetected
a 80% EtOH/0.1 N HCl and 90% EtOH/0.5 N HCl were used as
washing and elution solutions respectively.







(%)Chelator Concentration (μM) Temperature (°C) Time (min)
1 99 98 DOTA 1 95 10 0
2 99 98 DOTA 5 95 10 97
3 99 98 DOTA 10 95 10 98
4 99 98 DOTA 20 95 5 98b
5c 99 97 DOTA 10 95 10 99
6 99 98 NOTA 5 RTd 5 99
7 98 97 NOTA 1 RTd 5 95
8 99 97 NOTA 0.5 RTd 5 56
9 99 95 DOTATOC 14 95 10 97
10 99 95 DOTATOC 14 95 15 >99
a Washing solution was 1 mL of 80% ethanol/0.1 N HCl, elution solution was 0.5 mL of 90% ethanol/0.5 N HCl, buffer was 0.5 mL of NH4OAc
(1 M, pH 5). b The 68Ga elution was preheated for 10 min at 95 °C. c The monolith was reused (SiO2 monolith–SO3H).
d Room temperature.
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significantly higher than commonly reported values of 10–22
GBq μmol−1.32,33
These improved radiolabelling characteristics and shorter
reaction times will permit clinical application following a
simple pre-injection dilution of the radiopharmaceutical
when using ethanol as a solvent.12 The application of the
novel monolith column in this work showed that the 68Ga
radiolabelling characteristics of the processed solution could
be significantly improved, reducing the amount of chelator
and the reaction time required. It was also found that the
monolith could be reused with no significant reduction in la-
belling yield observed. This has not been reported for com-
mercial polymeric cation-exchange resin in ethanol-based
processing of 68Ga generator eluate.
In conclusion, a rapid, simple and efficient processing of
TiO2-based
68Ge/68Ga generator eluate was developed utilising
a novel cation-exchange silica-monolith column. It was dem-
onstrated that with an ethanol/HCl eluent the cation-
exchange silica-monolith could not only quantitatively re-
cover the 68Ga but also efficiently purify the 68Ga from other
metal ion impurities present in the initial generator eluate.
The advantage of monolith-based processing compared to
the optimum method reported in literature14 is a ca. 50% re-
duction in both the eluent volume and the HCl concentration
required. The higher 68Ga concentration and purity facilitates
efficient radiolabelling with the potential for significant in-
creases in specific activity which could dramatically improve
image quality for some tracers. The processed 68Ga was di-
rectly used for radiolabelling of commonly used chelators
DOTA and NOTA, showing significant improvement in reac-
tivity compared to other 68Ga3+ purification methods. Com-
parative radiolabelling of DOTATOC was performed to dem-
onstrate the utility of this method with a clinically relevant
example. The low back pressure of monolith based systems
compared to polymeric cation-exchange resins allows, for the
first time, the possibility to efficiently integrate an ion-
exchange component with a microfluidic reactor and the pro-
duction of automated modules for continuous 68Ga elution,
preparation and labelling. These applications and integrated
synthesis unit designs are under investigation.
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